BioSpace News Archive

“We delivered strong performance this quarter, with volume-driven growth across our core business and most major geographies.

Cerus Corporation announced that the U.S. Centers for Medicare & Medicaid Services has granted a new technology add-on payment for INTERCEPT Fibrinogen Complex within the Medicare Hospital Inpatient Prospective Payment System.

Codex DNA, Inc., the pioneer in automated benchtop synthetic biology systems, announced that it will release its second quarter 2021 financial results on Tuesday, August 10, 2021.

Synthetic Biologics, Inc. announced an amendment to the Company’s option for an exclusive license with Massachusetts General Hospital to include intellectual property and technology related to the use of SYN-020 intestinal alkaline phosphatase, the Company’s proprietary recombinant version of bovine IAP, to inhibit liver fibrosis in select diseases, including nonalcoholic fatty liver disease.

Ryvu Therapeutics announced today that it is scheduled to participate in the following investor conferences: 12th Annual Wedbush PacGrow Healthcare Conference on Tuesday, August 10, 2021.

Antibe Therapeutics Inc. has placed its absorption, metabolism and excretion (“AME”) study of otenaproxesul on a required pause because a pre-specified safety threshold was exceeded.

Arcturus Therapeutics Holdings Inc. announced that the Company has received approval for a Clinical Trial Application from the Singapore Health Sciences Authority to enable the advancement of two STARR™ mRNA vaccine candidates into the clinic.

Marinus Pharmaceuticals, Inc. today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of its lead product candidate ganaxolone, to treat seizures associated with CDKL5 deficiency disorder (CDD), a rare, genetic epilepsy.

ZyVersa is pleased to announce that Stephen C. Glover, ZyVersa’s Co-Founder, Chief Executive Officer, and Chairman, is an invited speaker at BTIG’s Virtual Biotechnology Conference 2021.

OpGen, Inc. today announced that its subsidiary Curetis GmbH and its instrument development and engineering partner have assembled 10 final pre-series release analyzer instruments of the Unyvero A30 RQ platform.